BPG is committed to discovery and dissemination of knowledge
Basic Study
Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Aug 15, 2026; 18(8): 123710
Published online Aug 15, 2026. doi: 10.4251/wjgo.123710
Figure 12
Figure 12  Effects of transforming growth factor-β1/Smad pathway inhibitor small-molecule inhibitor of Smad3 on epithelial-mesenchymal transition-related protein expression in HepG2 and PLC cells. A: Effects of transforming growth factor (TGF)-β1/Smad pathway inhibitor small-molecule inhibitor of Smad3 (SIS3) on epithelial-mesenchymal transition-related protein expression in HepG2 cells, measured by western blotting; B-E: SIS3 significantly downregulated expression of N-cadherin, vimentin and Slug, and significantly upregulated expression of E-cadherin in HepG2 cells; F: Effects of transforming growth factor-β1/Smad pathway inhibitor SIS3 on epithelial-mesenchymal transition-related protein expression in PLC cells, measured by western blotting; G-J: SIS3 significantly downregulated expression of N-cadherin, vimentin and Slug, and significantly upregulated expression of E-cadherin in PLC cells. cP < 0.001, dP < 0.0001. TGF-β1: Transforming growth factor-β1; TNS4: Tensin 4; OE: Overexpression; AAV8: Adeno-associated virus 8; SIS3: Small-molecule inhibitor of Smad3.


Write to the Help Desk